MedTrace Logo

The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer

NCT02809898 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2019-10-17

No results posted yet for this study

Summary

Our study aims to evaluate the role of ct-DNA and PBMC as biomarkers in the treatment of biliary tract cancer.

Conditions

  • Biliary Tract Neoplasms

Interventions

PROCEDURE

surgery or biopsy

Do radical surgery or biopsy to obtain a pathological result

Sponsors & Collaborators

  • Huadong Hospital

    collaborator OTHER

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • Yangpu District Central Hospital Affiliated to Tongji University

    collaborator OTHER

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Tao Chen, M.D. · Department of Biliary-pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02809898 on ClinicalTrials.gov